Premium
The optimal regimen of brentuximab vedotin for CD 30 + cutaneous lymphoma: are we there yet?
Author(s) -
Geller S.,
Myskowski P.L.,
Kim Y.H.,
Moskowitz A.,
Horwitz S.
Publication year - 2018
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.16052
Subject(s) - brentuximab vedotin , regimen , medicine , cd30 , oncology , lymphoma , dermatology